Showing 41 - 60 results of 80 for search '"Pharmacogenomics"', query time: 0.04s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44
  5. 45

    Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy by Y. Maor, S. Malnick

    Published 2013-01-01
    “…We discuss the mechanism of the hepatic injury, secondary to reactive oxygen species, and the spectrum of hepatic injury including, steatosis, steatohepatitis, hepatic sinusoidal injury and highlight the pharmacogenomics of such liver insults. Methods for reducing and treating the hepatotoxicity are discussed for specific agents including tamxifen and the newly introduced targeted antibodies.…”
    Get full text
    Article
  6. 46

    Genetic Variations Affect Chemotherapy Outcomes: A Role of the Spindle-assembly Checkpoint by Sinjini Sarkar, Ranita Pal, Trisha Choudhury, Manisha Vernekar, Partha Nath, Vilas D. Nasare

    Published 2024-04-01
    “…Cancer patients suffer from complicated chemotoxicity. Pharmacogenomics can help stratify patients by predicting their response to treatment and susceptibility toward severe side effects. …”
    Get full text
    Article
  7. 47

    Personalization of thiopurine therapy: Current recommendations and future perspectives by Urbančič Dunja, Pasha Flaka, Šmid Alenka, Mlinarič-Raščan Irena

    Published 2024-09-01
    “…This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, along side thiopurine S-methyltransferase activity and thiopurine metabolic profile. …”
    Get full text
    Article
  8. 48
  9. 49

    GTExome: Modeling commonly expressed missense mutations in the human genome. by Jill Hoffman, Henry Tan, Clara Sandoval-Cooper, Kaelyn de Villiers, Scott M Reed

    Published 2024-01-01
    “…The open-source tool is freely available at https://pharmacogenomics.clas.ucdenver.edu/gtexome/.…”
    Get full text
    Article
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55

    The impact of SLCO1B1 polymorphisms on homocysteine concentrations: evidence for a stronger association in men by Xinyuan Hu, Yanfang Jiang

    Published 2025-01-01
    “…In this study, we investigated the relationship between gene polymorphisms, particularly SLCO1B1 and homocysteine (Hcy) concentrations in ischemic stroke patients, with a focus on identifying potential risk factors for elevated Hcy levels.MethodsA total of 177 ischemic stroke patients, including 99 with single nucleotide polymorphisms (SNPs), underwent pharmacogenomics (PGx) sequencing tests, from September 2022 to November 2023 at the hospital. …”
    Get full text
    Article
  16. 56

    Extensive In Silico Analysis of ATL1 Gene : Discovered Five Mutations That May Cause Hereditary Spastic Paraplegia Type 3A by Mujahed I. Mustafa, Naseem S. Murshed, Abdelrahman H. Abdelmoneim, Miyssa I. Abdelmageed, Nafisa M. Elfadol, Abdelrafie M. Makhawi

    Published 2020-01-01
    “…In this study, the impact of nsSNPs in the ATL1 gene was investigated by various in silico tools that revealed five nsSNPs (V67F, T120I, R217Q, R495W, and G504E) are deleterious SNPs, which have a functional impact on ATL1 protein and, therefore, can be used as genomic biomarkers specifically before 4 years of age; also, it may play a key role in pharmacogenomics by evaluating drug response for this disabling disease.…”
    Get full text
    Article
  17. 57
  18. 58

    Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities by Nai Lee, Su‐jin Rhee, Seong Min Koo, So Won Kim, Gyo Eun Lee, Yoon A Yie, Yun Kim

    Published 2025-01-01
    “…We also discuss the role of model‐informed drug development, real‐world evidence, and pharmacogenomics in refining mAb dosing strategies. These insights underscore the importance of ongoing monitoring and data integration in the post‐marketing phase, providing a foundation for future precision medicine approaches in mAb therapy.…”
    Get full text
    Article
  19. 59
  20. 60